Related Experiment Videos
Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model
1Division of Infectious Diseases, University of Alabama School of Medicine, Birmingham.
Chemotherapy
|January 1, 1990
Summary
Daptomycin, a lipopeptide antibiotic, demonstrated equal effectiveness to vancomycin in treating staphylococcal bacteremia in mice. Both drugs significantly improved survival compared to no treatment.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Staphylococcal bacteremia is a serious infection often treated with vancomycin.
- Daptomycin is a novel lipopeptide antimicrobial agent with demonstrated activity against Gram-positive bacteria.
Purpose of the Study:
- To compare the efficacy of daptomycin with vancomycin in a murine model of staphylococcal bacteremia.
- To evaluate survival rates and serum drug levels in treated and control groups.
Main Methods:
- A murine model was used, with 299 mice inoculated with Staphylococcus bacteria.
- Two dosage regimens of daptomycin and vancomycin were administered over 14 days.
- Survival was assessed 31 days post-inoculation, and serum drug levels were monitored.
Main Results:
- No significant difference in survival was observed between daptomycin and vancomycin treatment groups at any dosage.
- Both daptomycin and vancomycin significantly increased survival rates compared to the untreated control group.
- Daptomycin maintained therapeutic serum levels for a longer duration than vancomycin.
Conclusions:
- Daptomycin is as effective as vancomycin in treating staphylococcal bacteremia in a murine model.
- Daptomycin represents a viable alternative treatment option for Gram-positive bacterial infections.